- Research grant empowers future leaders in clinical research to advance breakthroughs in the prevention, detection, diagnosis and treatment of NMIBC
- Two fellows to receive SUO NMIBC research grants through educational grant from Ferring Pharmaceuticals
“Advancing research in NMIBC is critical to addressing the significant unmet needs in this space. This fellowship provides an invaluable platform for collaboration and innovation, empowering the next generation of urologists to work alongside experienced mentors with a shared goal of driving progress that will ultimately improve patient outcomes,” said Sam S. Chang, MD, MBA, Chief Surgical Officer at the Vanderbilt Ingram Cancer Center and the Urologic Oncology Division Chief at Vanderbilt University Medical Center.To apply for the SUO NMIBC Fellows Research Grant, investigators may be working in basic, translational and clinical research field, and they must be working in a research environment capable of supporting transformational NMIBC research. All applications are due by Friday, February 27, 2026 by 5:00 PM U.S. Eastern Time. Applications will be evaluated by members of the Bladder Cancer Committee of the SUO on the merits of the research plan and project’s relevance to the prevention, detection, diagnosis, and/or treatment of NMIBC.
“Partnerships like this with the SUO are essential to advancing science and improving care for patients with NMIBC,” said Olga Tarasova, MD, MBA, U.S. Chief Medical Officer, Ferring Pharmaceuticals. “Through this grant, we are proud to support talented investigators whose work will shape the future of bladder cancer research.”
The award decision will be announced in May 2026, when the grant begins. Award recipients will present their research results at the conclusion of the award at the SUO Meeting at the 2027 American Urological Association Annual Meeting.
Source: Ferring. (2025). SUO and Ferring Pharmaceuticals Announce the SUO Non-Muscle Invasive Bladder Cancer (NMIBC) Fellows Research Grant. [Press Release]